Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

James Hamrick, MD, on how practicing oncologists and the FDA could utilize real world evidence

Dr. Hamrick, Senior Medical Director, Flatiron Health, offers opinion on how practicing oncologists and the FDA could utilize real world evidence

Published: 15 May 2018

Recent Videos: COA Conference Coverage

video

Jeff Vacirca, MD, discusses the capabilities of OneOncology's IT system

Dr. Vacirca, CEO, New York Cancer & Blood Specialists, Director, OneOncology, discusses the capabilities of OneOncology's IT system

video

Dan Wygal on how benefit design & value based contracting may make cancer drugs more affordable

Dan Wygal, Executive Director, Contract and Channel Strategy, AstraZeneca, offers opinion on how benefit design and value based contracting might ...

video

Jeff Vacirca, MD, explains the synergy between three cancer centers that make up OneOncology

Dr. Vacirca, CEO, New York Cancer & Blood Specialists, Director, OneOncology, explains the synergy between three cancer centers that make ...

video

Dan Wygal explains what AstraZeneca is doing to help make cancer drugs more accessible for patients

Dan Wygal, Executive Director, Contract and Channel Strategy, AstraZeneca, explains what AstraZeneca is doing to help make cancer drugs more ...

video

Jeff Vacirca, MD, explains why OneOncology is a unique practice model

Dr. Vacirca, CEO, New York Cancer & Blood Specialists, Director, OneOncology, explains why OneOncology is a unique practice model and ...

video

Dan Wygal provides perspective on value-based contracting in oncology

Dan Wygal, Executive Director, Contract and Channel Strategy, AstraZeneca, discusses value-based contracting in oncology

video

Jeff Vacirca, MD, regarding the novel practice models presented at COA 2019

Dr. Vacirca, CEO, New York Cancer & Blood Specialists, Director, OneOncology, describes some of the novel practice models presented at ...

video

Jax Zummo outlines some of the concerns with value-based contracting

Jax Zummo, Sr. Director, Corporate Affairs, Lilly Oncology, outlines some of the concerns with value-based contracting

video

Jax Zummo explains how value-based contracting works

Jax Zummo, Sr. Director, Corporate Affairs, Lilly Oncology, explains the function of value-based contracting

video

Jax Zummo provides opinion on how the pharmaceutical industry is helping community oncology

Jax Zummo, Sr. Director, Corporate Affairs, Lilly Oncology, considers how the pharmaceutical industry is helping community oncology thrive

Related Videos

video-image

Jeff Vacirca, MD, discusses the capabilities of OneOncology's IT system

video-image

Dan Wygal on how benefit design & value based contracting may make cancer drugs more affordable

video-image

Jeff Vacirca, MD, explains the synergy between three cancer centers that make up OneOncology

video-image

Dan Wygal explains what AstraZeneca is doing to help make cancer drugs more accessible for patients

video-image

Jeff Vacirca, MD, explains why OneOncology is a unique practice model

video-image

Dan Wygal provides perspective on value-based contracting in oncology

video-image

Jeff Vacirca, MD, regarding the novel practice models presented at COA 2019

video-image

Jax Zummo outlines some of the concerns with value-based contracting

video-image

Jax Zummo explains how value-based contracting works

video-image

Jax Zummo provides opinion on how the pharmaceutical industry is helping community oncology

video-image

Lee Schwartzberg, MD, explains the key drivers of success for OneOncology

video-image

Michael Schuh, BS, PharmD, MBA, discusses the latest advances in integrative medicine

video-image

Robin Shah considers how OneOncology is poised for growth

video-image

Lee Schwartzberg, MD, shares his goals as medical director of OneOncology

video-image

Michael Schuh, BS, PharmD, MBA, regarding supplements and integrative medicine in cancer care

video-image

Jax Zummo provides perspective on the rising cost of cancer drugs and patient access

video-image

Robin Shah regarding the capabilities of OneAnalytics

video-image

Lee Schwartzberg, MD, on how step therapy & utilization management are impacting community oncology

video-image

Michael Schuh, BS, PharmD, MBA, elaborates on integrative medicine

video-image

Jeff Patton, MD, considers whether OneOncology is open to growth in new markets

video-image

Kashyap Patel, MD, tells us how tele-medicine is changing the way cancer treatment is delivered

video-image

Christine Pfaff, RPh, explains how medically-integrated pharmacies improve cancer care

video-image

Jeff Patton, MD, shares details regarding OneOncology's advanced IT platform

video-image

Debra Patt, MD, evaluates the aggregation trends in community oncology

video-image

Kashyap Patel, MD, regarding two-sided risk and participation in the OCM

video-image

Christine Pfaff, RPh, discusses the challenges associated with medically-integrated pharmacies

video-image

Jeff Patton, MD, regarding key drivers of success for OneOncology

video-image

Debra Patt, MD, on why it is important for community oncologists to partner with associations

video-image

Kashyap Patel, MD, explains how practices can leverage data to negotiate stronger payer contracts

video-image

Christine Pfaff, RPh, explains why cancer centers should embrace medically-integrated pharmacies

video-image

Jeff Patton, MD, on why community oncologists should embrace novel practice models

video-image

Debra Patt, MD, regarding important policy updates coming out of COA 2019

video-image

Kashyap Patel, MD, offers opinion on novel practice models

video-image

Christine Pfaff, RPh, on how COPA is helping community oncology manage their dispensing pharmacies

video-image

Jeff Patton, MD, considers some of the important challenges & solutions for community oncology

video-image

Debra Patt, MD, shares some of the important takeaways from the 2019 COA Conference

video-image

Kashyap Patel, MD, discusses keys to success for today's oncology practices

video-image

Sonia Oskouei, PharmD, DPLA, elaborates on the reimbursement challenges facing biosimilars

video-image

Sonia Oskouei, PharmD, DPLA, speculates on the future of biosimilars

video-image

Ted Okon reflects on past victories for COA and speculates on future progress

video-image

Sonia Oskouei, PharmD, DPLA, on the clinical challenges associated with the adoption of biosimilars

video-image

Ted Okon on what community oncologists should know about the recent PBM hearings

video-image

Sonia Oskouei, PharmD, DPLA, on the differences between approval for biologics & biosimilars

video-image

Ted Okon on the scope of the step therapy & utilization management concern for community oncologists

video-image

Jonathan Levitt explains how DIR fees are impacting community oncology

video-image

Ted Okon on whether there is a disconnect between policy & the realities of community oncology

video-image

Jonathan Levitt considers how state legislation regarding community oncology has changed

video-image

John Frownfelter, MD, FACP, on how AI is bringing about a better understanding of the cancer patient

video-image

Jonathan Levitt on what has happened in the last 6 months with PBMs & state Medicaids

video-image

John Frownfelter, MD, FACP, outlines some of the hurdles AI has introduced into clinical practice

video-image

Ben Jones considers recent policy changes of which oncologists should be aware

video-image

John Frownfelter, MD, FACP, explains how artificial intelligence is contributing to value-based care

video-image

Ben Jones offers his opinion on priority policy concerns

video-image

John Frownfelter, MD, FACP, explains how artificial intelligence is being applied to cancer care

video-image

Nicolas Ferreyros, on the influence of pharmacy benefit managers

video-image

Ira Klein, MD, MBA, FACP, on embracing value-based oncology care

video-image

Nicolas Ferreyros, on what oncologists should know about their federal policymakers

video-image

Ira Klein, MD, MBA, FACP, provides perspective on the rising cost of cancer drugs

video-image

Nicolas Ferreyros, explains why oncologists should communicate with their local representatives

video-image

Ira Klein, MD, MBA, FACP, on the role of value in cancer drug development

video-image

Melissa Johnson, MD, shares her thoughts on biomarker development in NSCLC

video-image

Melissa Johnson, MD, speculates on exciting developments in the treatment of NSCLC

video-image

Anshu Jain, MD, tells us what physicians & payers should know about proton therapy

video-image

Melissa Johnson, MD, on the updated NCCN guidelines in regards to PD-L1 testing

video-image

Anshu Jain, MD, on the current controversy regarding proton therapy in cancer care

video-image

Melissa Johnson, MD, considers the recent data investigating atezolizumab in SCLC

video-image

Anshu Jain, MD, explains why proton therapy is important in terms of delivery & outcomes

video-image

Robert E. Baird, Jr., RN, MSA, CASC, shares how COA is supporting Dayton Physicians Network

video-image

Matthew Hall, MD, tells us what physicians & payers should know about proton therapy

video-image

Robert E. Baird, Jr., RN, MSA, CASC, shares key takeaways from the 2019 COA Annual Conference

video-image

Matthew Hall, MD, considers whether the application of proton therapy is growing

video-image

Lakshmi Aggarwal, MD, explains why transparency is necessary in the healthcare system

video-image

Matthew Hall, MD, on the difference between photon therapy & proton therapy

video-image

Lakshmi Aggarwal, MD, considers the role of politics in oncology

video-image

Lucio Gordan, MD, shares how the shift in site of care is impacting community oncology

video-image

Lakshmi Aggarwal, MD, offers opinion on the evolving landscape of oncology

video-image

Lucio Gordan, MD, explains how practices should leverage their OCM performance data

video-image

Jesse Dresser evaluates the impact of payer trends on drug manufacturers' market access strategy

video-image

Lucio Gordan, MD, on best practices in delivering value-based care

video-image

Jesse Dresser shares what legal tools are available to dispensing oncology practices & pharmacies

video-image

Lucio Gordan, MD, describes the primary drivers of the cost of cancer care

video-image

Jesse Dresser considers the challenges for dispensing oncology practices regarding payer networks

video-image

Kathy Gaughran explains how Healthcare Success is helping community oncologists

video-image

Jesse Dresser on the trends he is observing between payers and dispensing practices & pharmacies

video-image

Bobbi Buell, MBA, regarding the biggest changes & challenges in oncology reimbursement in 2019

video-image

Sibel Blau, MD, on the pros & cons associated with participation in a clinically integrated network

video-image

Sean Brusky explains how the pharmaceutical industry is working to help community oncology

video-image

Sibel Blau, MD, elaborates on clinically integrated networks

video-image

Sean Brusky provides Genentech’s perspective on the rising cost of cancer drugs and patient access

video-image

Sibel Blau, MD, tells us more about IQ Oncology

video-image

Sean Brusky on taking value into consideration when developing cancer drugs

video-image

Sibel Blau, MD, shares what the QCCAN is doing for participating members

video-image

Michael Diaz, MD, on how community oncology is shaping the future of cancer care

video-image

Michael Diaz, MD, regarding high priority policy initiatives for COA

video-image

Michael Diaz, MD, articulates his goals for the coming year as president of COA

video-image

Michael Diaz, MD, shares exciting updates from the 2019 Community Oncology Conference

video-image

Stephen Schleicher, MD, MBA, regarding participation in a two-sided risk model

video-image

Stephen Schleicher, MD, MBA, discusses participation in the Oncology Care Model

video-image

Stephen Schleicher, MD, MBA, on the challenges associated with value-based care